Baicalin is a flavonoid compound extracted from the roots of Scutellaria baicalensis (Chinese skullcap), a plant widely used in Traditional Chinese Medicine (TCM). Its application for liver-related ailments, including hepatitis, is documented both in traditional practice and in scientific literature. Modern research has explored baicalin’s effects on hepatitis primarily in preclinical (cell and animal) studies, with some small-scale clinical research.

Scientifically, baicalin demonstrates antiviral, anti-inflammatory, and hepatoprotective properties. In vitro studies show that baicalin can inhibit replication of hepatitis B virus (HBV) and hepatitis C virus (HCV) by interfering with viral polymerase activity and modulating host immune responses. Animal models of hepatitis indicate that baicalin administration reduces liver inflammation, oxidative stress, and fibrosis. These effects are attributed to the suppression of inflammatory cytokines (such as TNF-α and IL-6) and downregulation of pathways like NF-κB.

Some clinical studies from China suggest potential benefit of baicalin or baicalin-containing herbal formulas in improving liver function in hepatitis patients; however, these studies are generally small, lack rigorous controls, and often use combination products, making it difficult to attribute effects solely to baicalin. Systematic reviews highlight the need for more robust, large-scale human trials.

In summary, there is preclinical and early clinical evidence suggesting baicalin may help support liver health in hepatitis, but high-quality clinical validation is limited. Its use for hepatitis is better supported by scientific evidence than by tradition alone, but the overall strength of evidence is moderate.